

Shahid A Khan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8396247/shahid-a-khan-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

4,639
citations

17
h-index

39
g-index

39
ext. papers

6,127
ext. citations

8.2
avg, IF

5.71
L-index

#	Paper	IF	Citations
36	Cholangiocarcinoma. <i>Lancet, The</i> , 2005 , 366, 1303-14	40	914
35	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014 , 60, 1268-89	13.4	815
34	Cholangiocarcinoma - evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 95-111	19.4	599
33	Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. <i>Gut</i> , 2012 , 61, 1657-69	19.2	551
32	Changing international trends in mortality rates for liver, biliary and pancreatic tumours. <i>Journal of Hepatology</i> , 2002 , 37, 806-13	13.4	436
31	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588	24.2	355
30	Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. <i>Journal of Hepatology</i> , 2012 , 56, 848-54	13.4	206
29	Cholangiocarcinoma: Epidemiology and risk factors. <i>Liver International</i> , 2019 , 39 Suppl 1, 19-31	7.9	181
28	Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020 , 72, 95-103	13.4	102
27	A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. <i>American Journal of Gastroenterology</i> , 2014 , 109, 76-84	0.7	84
26	Multivalent nanoparticle networks enable point-of-care detection of human phospholipase-A2 in serum. <i>ACS Nano</i> , 2015 , 9, 2565-2573	16.7	82
25	p53 Mutations in human cholangiocarcinoma: a review. <i>Liver International</i> , 2005 , 25, 704-16	7.9	56
24	Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 733-8	2.2	39
23	In vivo and in vitro nuclear magnetic resonance spectroscopy as a tool for investigating hepatobiliary disease: a review of H and P MRS applications. <i>Liver International</i> , 2005 , 25, 273-81	7.9	34
22	Cholangiocarcinoma. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 65	51.1	30
21	Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1544-53	5.6	27
20	Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2019 , 116, 56-66	7.5	25

19	Viral hepatitis prevalence in patients with active and latent tuberculosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 8920-6	5.6	13
18	Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. <i>Journal of Clinical and Experimental Hepatology</i> , 2019 , 9, 740-748	4.1	12
17	The risk factors and diagnosis of cholangiocarcinoma. <i>Hepatology International</i> , 2013 , 7, 377-93	8.8	12
16	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. <i>Translational Research</i> , 2017 , 183, 137-154	11	10
15	Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019 , 71, 1261-1262	13.4	7
14	Plasma Lipid Profiling in a Rat Model of Hepatocellular Carcinoma: Potential Modulation Through Quinolone Administration. <i>Journal of Clinical and Experimental Hepatology</i> , 2015 , 5, 286-94	4.1	7
13	Analysis of p53 mutations for a mutational signature in human intrahepatic cholangiocarcinoma. <i>International Journal of Oncology</i> , 2006 , 28, 1269-77	1	7
12	Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase. <i>Nanoscale</i> , 2016 , 8, 11834-9	7.7	6
11	Epidemiology of HPB malignancy in the elderly. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 503-513	3.6	5
10	Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a Risk Factor for Cholangiocarcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2019 , 9, 171-175	4.1	4
9	Exploring Metabolic Consequences of and Dysregulation in Hepatocellular Carcinoma by Network Reconstruction. <i>Journal of Hepatocellular Carcinoma</i> , 2020 , 7, 1-9	5.3	3
8	Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. <i>BMJ Open Gastroenterology</i> , 2020 , 7,	3.9	3
7	The role of miRNAs in cholangiocarcinoma. <i>Hepatic Oncology</i> , 2016 , 3, 167-180	4	3
6	Cholangiocarcinoma miscoding in hepatobiliary centres. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 635-639	3.6	3
5	Reply to: Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis] <i>Journal of Hepatology</i> , 2020 , 72, 1217	13.4	2
4	Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England. <i>Diabetes Research and Clinical Practice</i> , 2017 , 132, 102-107	7.4	2
3	Photodynamic therapy significantly improves survival outcomes in people with non-resectable cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2004 , 30, 315-8	14.4	1
2	Mutations in circulating cell-free tumour DNA: Predictors of survival in hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021 , 2, 54-62	0.8	1

1 The view from the United Kingdom 24-28